logo
Why did Fed keep interest rates unchanged despite Trump's pressure?

Why did Fed keep interest rates unchanged despite Trump's pressure?

Time of India6 days ago
The Federal Reserve maintained its key short-term interest rate, defying President Trump's persistent calls for a reduction. The rate remains at 4.3%, a level established after three cuts last year, with officials citing the need to assess the impact of Trump's tariffs on inflation and the economy.
Tired of too many ads?
Remove Ads
Washington: The Federal Reserve left its key short-term interest rate unchanged for the fifth time this year, brushing off repeated calls from President Donald Trump for a cut.The Fed's decision Wednesday leaves its key short-term rate at about 4.3%, where it has stood after the central bank made three cuts last year. Chair Jerome Powell has said the Fed would likely have cut rates already if not for Trump's sweeping tariffs. Powell and other Fed officials say they want to see how Trump's duties on imports will impact inflation and the broader economy. So far the duties have lifted costs of some goods, such as appliances, furniture, and toys, and overall inflation has risen a bit, though less than many economists had expected.There were some signs of splits in the Fed's ranks: Governors Christopher Waller and Michelle Bowman voted to reduce borrowing costs, while nine officials, including Powell, favoured standing pat. It is the first time in more than three decades that two of the seven Washington-based governors have dissented. One official, Governor Adriana Kugler, was absent and didn't vote.The choice to hold off on a rate cut will almost certainly result in further conflict between the Fed and White House, as Trump has repeatedly demanded that the central bank reduce borrowing costs as part of his effort to assert control over one of the few remaining independent federal agencies.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New 'Khalistan embassy' in Canada threatens India-Canada ties again
New 'Khalistan embassy' in Canada threatens India-Canada ties again

Business Standard

time20 minutes ago

  • Business Standard

New 'Khalistan embassy' in Canada threatens India-Canada ties again

Just as India and Canada were making cautious moves to improve strained ties, visuals of an 'Embassy of the Republic of Khalistan' on Canadian soil have risked derailing hard-earned diplomatic progress. Radical Sikh groups in British Columbia have established what they describe as the 'Embassy of the Republic of Khalistan'. Photographs accessed by India Today show that the self-proclaimed embassy is located inside a section of the Guru Nanak Sikh Gurdwara in Surrey. The same gurdwara was once led by Hardeep Singh Nijjar, a pro-Khalistan figure whom Indian authorities had labelled a terrorist. Nijjar was shot dead in 2023 in the gurdwara's car park, setting off a chain of events that pushed India-Canada relations into a deep freeze. The announcement of the so-called 'embassy' coincides with preparations for a 'Khalistan referendum' organised by Sikhs for Justice (SFJ), a group banned in India. According to reports, Indian security agencies are keeping a close watch. Diplomatic thaw under threat The development comes at a time when ties between the two countries had shown tentative signs of a thaw. Prime Minister Narendra Modi and Canada's newly-elected Prime Minister Mark Carney met face-to-face during the G7 summit earlier this year — their first such meeting since tensions escalated. Both sides had indicated a willingness to move beyond the fallout from Nijjar's killing and the allegations made by former Canadian Prime Minister Justin Trudeau, who had accused the Indian government of involvement in the murder — a charge New Delhi has firmly denied. Canadian intelligence backs India's security concerns India has long raised concerns about Khalistani groups using Canadian soil as a safe haven for promoting separatist ideology, fundraising, and plotting acts of violence. It has consistently criticised Canadian authorities for alleged inaction. In a notable shift, Canadian authorities have acknowledged these concerns. In June 2025, the Canadian Security Intelligence Service (CSIS) officially recognised the threat posed by Khalistani extremists operating within Canada. Its annual report stated: 'Khalistani extremists continue to use Canada as a base for the promotion, fundraising or planning of violence primarily in India.' While no attacks linked to Canada-based Khalistani extremists (CBKEs) occurred in 2024, CSIS warned that such actors remain active in global financing and operational planning. This marked the first time the Canadian government has officially used the term 'extremism' in the context of the Khalistan movement. CSIS described Canada-based Khalistani extremists as a core element of the country's politically motivated violent extremism (PMVE) threat. According to the agency, PMVE groups aim to use violence to create new political systems or structures, often through cross-border efforts. Khalistani actors, the agency warned, continue to engage in 'planning, financing and facilitating attacks globally' in pursuit of a separate Khalistan state, primarily carved out of India's Punjab region.

Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26

Business Standard

time20 minutes ago

  • Business Standard

Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26

Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.

Assetz acquires 11.5 acres in Bengaluru for ₹1,400 crore housing project
Assetz acquires 11.5 acres in Bengaluru for ₹1,400 crore housing project

Business Standard

time20 minutes ago

  • Business Standard

Assetz acquires 11.5 acres in Bengaluru for ₹1,400 crore housing project

Bengaluru-based real estate developer Assetz has acquired an 11.5-acre land parcel on Old Madras Road (OMR)–Hoskote Highway in East Bengaluru to develop a luxury residential community with an estimated gross development value (GDV) exceeding ₹1,400 crore. The strategic move is backed by Motilal Oswal Alternates (MOA). The company stated that the acquisition includes a joint development component with Vanshee Builders & Developers Pvt Ltd. The upscale residential project, featuring highway-facing support amenities, will span 1.4 million square feet of saleable built-up area (SBA) and comprise approximately 800 units. This move further strengthens Assetz's position in East Bengaluru — a market where it has already made a mark with projects such as Marq, Bloom & Dell, Sun & Sanctum, 66, and Shibui. 'Strategic land acquisition has always been fundamental to our development approach, laying the groundwork well before execution begins. In the past two years alone, we have secured a pipeline of 17 million square feet across 19 projects with the potential to deliver 9,000 homes. With 10 launches this year, we are committed to delivering homes that offer long-term value to our buyers and communities alike,' said Sunil Pareek, executive director, Assetz. In July, Motilal Oswal Alternates closed its sixth real estate fund with a corpus of ₹2,000 crore. Anand Lakhotia, managing director and co-head (real estate) at Motilal Oswal Alternates, commented, 'We are well-positioned to support quality land acquisitions. This association reflects our belief in Assetz's vision of a professional residential platform with established execution capabilities. Their emphasis on good governance, supported by a steady track record, is in line with our strategy of investing in top-performing developers.' Since 2006, Assetz has delivered 20 residential and commercial projects totalling approximately 15 million square feet. In the residential segment, the company has continued to scale, building a portfolio of 46 projects — delivered, launched, and under approval — with a cumulative development potential of 45 million square feet.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store